



Design Therapeutics to Participate in Upcoming Investor Conferences

November 26, 2025

CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences:

- **Piper Sandler 37th Annual Healthcare Conference** on Wednesday, December 3, 2025, at 3:30 p.m. ET in New York, NY
- **Evercore 8th Annual Healthcare Conference** on Thursday, December 4, 2025, at 10:00 a.m. ET in Coral Gables, FL

Live webcasts of each fireside chat will be available [here](#) and in the investors section of the company's website at www.designtx.com. The webcasts will be archived for at least 30 days following each presentation.

About Design Therapeutics

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC[®] gene targeted chimera small molecules. The company's GeneTAC[®] molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC[®] programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing DT-818 for myotonic dystrophy type-1, and a program in Huntington's disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.

Contact:

Renee Leck
THRUST Strategic Communications
renee@thrustsc.com